Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of December due to the new share issue carried out in connection with the listing of Q-linea’s shares on Nasdaq Stockholm. A total of 8,088,235 share have been added.
At 28 December 2018, which is the last trading day in December, the number of shares and votes amounts to 22,906,915.
For further information, please contact:
Anders Lundin, CFO and IR
Telephone: +46 706 00 15 20
This information is information that Q-linea AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on 28 December 2018 at 08.30 AM CET
Q-linea AB is a diagnostics company focused on developing and delivering solutions for healthcare providers, enabling them to accurately diagnose and treat infectious diseases in the shortest possible time. Our core product, ASTar™, is a system for rapid and automatic determination of the most effective antibiotic treatment against infectious diseases. The Company was founded in 2008 and its operations were based on technology developed by scientists from the Rudbeck Laboratory at Uppsala University, together with other companies such as Olink Bioscience AB and Uppsala University’s holding company, UUAB.